Return of reproductive performance after expectant management and local treatment for ectopic pregnancy.
The purpose of this study was to examine hysterosalpingographic findings and reproductive performance in patients previously managed non-surgically for ectopic pregnancy. Forty-nine patients with unruptured ectopic pregnancies were treated either by expectant management (n = 16) or medically (n = 33), using transvaginal methotrexate or sulprostone injection. The treatment was successful in 35 patients (71.5%), 12 out of 16 and 23 out of 33 in the two groups respectively. For all patients, follow-up currently varies from 3 to 52 months with a median follow-up of 16.6 +/- 11.2 months and 7.3 +/- 4.3 months in the two groups respectively. Hysterosalpingography was performed in 25 out of 26 patients who desired further pregnancy. We found evidence of tubal patency on the ectopic pregnancy treated side in 23 cases (92%). In this group, no recurrent ectopic pregnancy was observed. In the expectant management group, eight out of nine patients became pregnant, and the mean time to achieve pregnancy was 16.6 +/- 11.2 months. In the medical treatment group, eight out of 17 patients became pregnant and the mean time to achieve pregnancy was 8.6 +/- 4.2 months. In this last group, seven out of nine non-pregnant patients have had only a short follow-up, 4.5 +/- 3.2 months since treatment completion. No recurrent ectopic pregnancy was observed in this successfully treated group of patients who desired further pregnancy. We conclude that the medical approach to unruptured ectopic pregnancy is associated with a high rate of tubal patency and a reproductive performance similar to conservative surgical methods.
Fernandez
H
H
Department of Obstetrics and Gynaecology, Hôpital Antoine Béclère, Clamart, France.
Lelaidier
C
C
Baton
C
C
Bourget
P
P
Frydman
R
R
D000328:Adult; D015232:Dinoprostone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005186:Fallopian Tube Patency Tests; D005260:Female; D005298:Fertility; D005500:Follow-Up Studies; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D011271:Pregnancy, Ectopic / Q000503:physiopathology / Q000628:therapy*; D011336:Probability
C016767:sulprostone; D015232:Dinoprostone; D008727:Methotrexate